AI Article Synopsis
- Incretin-based therapies, like sitagliptin (a DPP-4 inhibitor), have recently become available in Japan for treating type 2 diabetes.
- After an Oral Glucose Tolerance Test (OGTT), sitagliptin increases active GLP-1 levels about twofold and has proven effective both alone and with other medications in clinical trials.
- While sitagliptin hasn't increased hypoglycemic events in monotherapy, severe cases have been reported in older Japanese patients on high doses of sulfonylureas, indicating the need for long-term effectiveness studies in this population.
Article Abstract
Recently, incretin-based therapies have become available for patients with type 2 diabetes in Japan. Sitagliptin is one of several DPP-4 inhibitors. After an OGTT, active endogenous GLP-1 concentrations are increased about twofold by sitagliptin. In clinical trials, sitagliptin was shown to be effective in monotherapy and in combination with other oral agents. Hypoglycemic events were not increased in monotherapy. However in Japan, severe hypoglycemic events have been reported especially in older patients with high dose of sulfonylurea. The long-term effectiveness needs to be evaluated in Japanese patients with type 2 diabetes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Congenital disorders of glycosylation type 1A associated with cerebral hemorrhagic infarction: illustrative case.
J Neurosurg Case Lessons
January 2025
Department of Neurosurgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Background: Cases of congenital disorders of glycosylation (CDGs) are rare, and the occurrence of hemorrhagic infarction is also rare. The etiology is unclear.
Observations: A 3-year-old Asian boy with CDG type 1A was hospitalized with pneumonia.
Examining the Emotional and Physical Health Impact in Users of Open-Source Automated Insulin Delivery and Sources of Support: Qualitative Analysis of Patient Narratives.
J Med Internet Res
January 2025
Diabetes Management Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
Background: Although commercially developed automated insulin delivery (AID) systems have recently been approved and become available in a limited number of countries, they are not universally available, accessible, or affordable. Therefore, open-source AID systems, cocreated by an online community of people with diabetes and their families behind the hashtag #WeAreNotWaiting, have become increasingly popular.
Objective: This study focused on examining the lived experiences, physical and emotional health implications of people with diabetes following the initiation of open-source AID systems, their perceived challenges, and their sources of support, which have not been explored in the existing literature.
Purpose: overexpression/amplification in wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising responses to dual-HER2 inhibition; however, comparative efficacy has not been investigated. We conducted a randomized phase II trial to evaluate efficacy and safety of dual-HER2 inhibition against standard-of-care anti-EGFR antibody-based therapy as second/third-line treatment in HER2-positive mCRC.
Methods: Patients with -WT mCRC after central confirmation of HER2 positivity (immunohistochemistry 3+ or 2+ and in situ hybridization amplified [HER2/CEP17 ratio >2.
Clinical Impact of Pancreatic and Peripancreatic Hemorrhage Associated With Acute Pancreatitis.
J Comput Assist Tomogr
November 2024
NYU Department of Radiology, New York, NY.
Purpose: The significance of pancreatitis-associated hemorrhage outside the context of a ruptured pseudoaneurysm remains unclear. This study aims to characterize the clinical significance of pancreatic hemorrhage during acute pancreatitis (AP).
Methods: This retrospective study included adult patients diagnosed with hemorrhagic pancreatitis (HP) from 2010 to 2021.
Chimeric antigen receptor therapy in hematologic malignancies.
JAAPA
January 2025
In the PA program at the University of Florida in Gainesville, Fla., Elizabeth Brownlee is director of didactic education and Melissa Turley is interim program director and a clinical assistant professor. Heather Nations practices in obstetrics and gynecology at UF Health Physicians in Gainesville. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Chimeric antigen receptor (CAR) T-cell therapy has led to significant advances in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma, and now shows promise for solid tumors. This type of immunotherapy can achieve high response rates in patients with hematologic malignancies, but carries serious adverse reactions, including cytokine release syndrome and immune-effector cell-associated neurotoxicity syndrome. This article describes CAR T-cell therapy, guidance for primary care providers caring for patients undergoing therapy, and the ongoing need for research to enhance CAR T-cell therapy's safety and effectiveness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!